If you're over 50, the shingles shot is one of the highest-payoff things you can do this year — overwhelming evidence, near-zero cost on Medicare or commercial insurance, and the dementia data is starting to look real. If you're over 75, the RSV shot belongs next to it. The single honest catch is the shingles second dose: ~80% of recipients describe 24–72 hours of feeling fluish, so plan around a work day. That's the bill. The trade is a disease that hits 1 in 3 Americans over their lifetime and a respiratory infection that puts 100,000+ older adults in the hospital each US winter.
Both vaccines target a specific problem with the older immune system: it loses the ability to keep certain viruses in check. For shingles, the virus is one you already have. Anyone who had chickenpox as a kid is carrying varicella-zoster virus, dormant, in the nerve roots near the spinal cord. Your T cells keep it suppressed. In your 50s those T cells start to lose interest, and the virus can wake up — usually as a stripe of agonizing rash on one side of the body, sometimes worse. The shingles shot rebuilds the specific immune response that was failing. It uses a piece of the virus (not a live virus) paired with a strong adjuvant — the AS01 system — that punches the immune system hard enough to recover the response. The hard punch is also why you feel rough for a day or two afterward.
RSV is the opposite story: it's a virus you'll meet again, every winter, whether you remember it or not. RSV is the leading cause of cold symptoms in toddlers and a known nuisance in adults, but in older lungs it isn't a nuisance — it's pneumonia, COPD flare, heart-failure trigger, ICU stay. The reason no RSV vaccine existed before 2023 is that the surface protein you want to immunize against (the F protein) changes shape after it fuses with a cell, and decades of vaccine candidates trained the immune system on the wrong shape. Researchers figured out how to lock the protein in its pre-fusion shape — the shape that's actually visible on incoming virus. All three approved RSV shots (GSK's Arexvy, Pfizer's Abrysvo, Moderna's mResvia) use this trick.
What the trials actually showed
For the shingles shot, the numbers are unusually big. In the two pivotal trials — the larger one in adults 50 and over, the smaller one in adults 70 and over — the vaccine cut shingles cases by 97% in the younger group and 91% in the older one. Crucially, efficacy barely fell with age. Most vaccines fade in the very old immune system; the AS01 adjuvant is what keeps this one working in 80-year-olds. Postherpetic neuralgia — the months-to-years of nerve pain that's the actually-frightening part of shingles — was cut by about 90%.
For the RSV shots, the numbers are also big — just one season at a time. Against the version of RSV that actually puts you in the hospital, the GSK vaccine was 82% effective in the first season after the shot, and 94% effective against severe disease. The Pfizer vaccine was 67% against milder lower-respiratory illness and 86% against the more severe end. Real-world data after the 2023 and 2024 RSV seasons confirmed the trial numbers held up against hospitalization specifically, which is the endpoint that matters. The catch is that protection wanes — second-season effectiveness drops to roughly half of first-season, and faster in the very elderly. Whether to give a booster dose is still being worked out.
There's also a more surprising piece of evidence on the shingles shot worth knowing about. In Wales, a national rollout used date of birth as the eligibility cutoff — born one week before the cutoff, never offered the vaccine for life; one week after, offered it. That's an accidental randomized trial baked into the policy. Following both groups for seven years, the people offered the shingles shot had 20% less dementia. A separate analysis of US electronic health records found people who got the newer Shingrix had 17% more dementia-free time than people who'd gotten the older shingles vaccine. The mechanism isn't pinned down (probably some mix of preventing nerve inflammation from reactivated virus and the adjuvant's general immune effects) but the signal is unusually clean for observational data.
What you skip if you skip these
Roughly one in three Americans gets shingles in their lifetime, and by age 85 it's closer to one in two. For most people the experience is a stripe of blisters on one side of the torso, two to four weeks of pain bad enough to disrupt sleep, and then it clears. For 10 to 18% — and the percentage climbs every decade after 50 — the pain doesn't clear. Postherpetic neuralgia is months to years of burning, electric pain along the same nerve, often poorly responsive to standard painkillers. People describe it as the thing that finally made them stop working, or stop driving, or stop sleeping in the same bed as their spouse. Less common but worse outcomes: shingles in the eye that scars the cornea and takes vision; facial-nerve shingles that leaves a permanent partial face droop; a measurable spike in stroke risk in the three months after.
RSV plays a different timeline. You'll probably never know which winter cold was the RSV one — until the one that isn't a cold. In adults 75 and over, RSV causes somewhere between 60,000 and 160,000 US hospitalizations and 6,000 to 10,000 deaths every year. Among the older adults who get hospitalized with RSV, about 1 in 6 ends up in intensive care and about 1 in 20 dies. The deaths and ICU stays are concentrated in people with COPD, heart failure, or diabetes — the exact people who feel "fine, just dealing with my regular stuff" and don't take a cold seriously. RSV is also a leading reason older adults walk into a hospital on their own feet and walk out three weeks later having lost a chunk of their independence — the post-hospital functional decline that often doesn't fully recover.
The dementia angle, if it holds up, changes the stakes calculation again. A 20% relative reduction in incident dementia over seven years is the kind of effect size you'd see from a dedicated dementia drug, except this isn't a drug — it's a shot you were going to get for shingles anyway.
What to actually do
The protocol is short. The hard part is finishing it.
Who: Shingles vaccine is recommended for all immunocompetent adults 50 and over, with no upper age limit, and for adults 19 and over with a weakened immune system. RSV vaccine is recommended for all adults 75 and over, and for adults 50 to 74 with risk-elevating conditions — which in practice covers a lot of people, including anyone with COPD, asthma severe enough to need maintenance medication, congestive heart failure, diabetes, chronic kidney or liver disease, immune compromise, severe obesity, or living in a nursing home or assisted living. If you're under 75 and any of those apply, ask — and if you're genuinely unsure whether you're old enough or sick enough to qualify yet, the RSV-shot eligibility rules are worth walking through before you assume you're out.
When not to do it (or to do it carefully)
Pregnancy and breastfeeding are not contraindications in any meaningful sense for this entry's target reader — the relevant age band starts at 50. The shingles vaccine contains no live virus and is explicitly safe in people with weakened immune systems, including transplant recipients, cancer patients, and people on immunosuppressive medications.
What people get wrong
"I already had shingles, so I'm immune." No — recurrence happens in roughly 5 to 10% of people within 8 years, and the recommendation is to get vaccinated regardless of prior shingles. Wait until the active rash has resolved, then go in.
"I got the old shingles shot (Zostavax) years ago, I'm covered." No — Zostavax was a different vaccine (live, single-dose), it worked much less well, and protection faded fast. The current recommendation is to get the two-dose Shingrix series regardless of prior Zostavax. The older shot was discontinued in the US in 2020.
"RSV is just a cold for adults." For most adults under 60 with healthy lungs, yes. For adults 75 and over, or anyone with chronic lung or heart disease at any age, no. RSV hospitalizes more older adults than influenza in some years, and per-hospitalization mortality is similar to flu.
"The Guillain-Barré warning means the RSV shot isn't worth it." A real signal, but quantitatively tiny next to what RSV itself does. The FDA's own analysis estimated 7–9 extra GBS cases per million doses; RSV causes thousands of deaths per year in the same age band that the warning applies to. The math isn't close.
"I should wait until I'm older." Wrong direction. Both vaccines work best when your immune system can still mount a strong response. Vaccinating at the floor of the eligibility window (50 for shingles, 60–75 for RSV depending on risk) captures more lifetime benefit than waiting until you're 80.
Where this goes wrong in practice
The single biggest failure mode is the shingles second dose. The first dose is easy — your doctor mentions it, you swing by the pharmacy, done. Then two months later your arm is still tender from the first dose, you remember the day you spent on the couch, and you start putting it off. The protection drops sharply from two doses to one. Set the reminder when you book the first one. Some pharmacies will book the second appointment automatically; let them.
The second failure is the "I'll get to it" loop on RSV. RSV season is a real season — roughly late October through April in the US — and the vaccine works best when antibody levels are already up when you encounter the virus. If you book the shot in February, you've missed most of the season. The window worth aiming for is August through October.
The third, RSV-specific: the very elderly and the immunocompromised — the people who most need protection — also have the steepest waning. If you got the RSV vaccine in 2023 and you're 82 with COPD, talk to your doctor about whether to consider revaccination once ACIP weighs in on boosters, which is an open question as of 2025.
The fourth: skipping because of the day-after symptoms from the first shingles dose. The reactogenicity tells you the vaccine is doing what it's supposed to — the adjuvant is loud, that's the design. It's also why this vaccine works in 80-year-olds when the older one didn't. Plan around it, don't skip because of it.
Cost, where, how
For most readers in the target age band, the out-of-pocket cost of both vaccines is zero. The Inflation Reduction Act eliminated cost-sharing for all ACIP-recommended adult vaccines under Medicare Part D starting 1 January 2023 — meaning anyone with Medicare prescription drug coverage pays nothing for either vaccine. Commercial insurance under the Affordable Care Act's preventive-services rule covers the same vaccines without copay. The catch: Medicare Part B (the medical-services side) does not cover shingles or RSV vaccines, so they have to be billed through Part D, which is set up at pharmacies. About 95% of Medicare-covered shingles doses are administered at chain pharmacies for this reason.
List prices, if you're paying cash: about $200 per Shingrix dose ($400 for the two-dose series) and roughly $280–$320 per RSV dose. Manufacturer assistance programs exist for the uninsured.
You don't need a doctor's appointment. Walk in to CVS, Walgreens, Costco, Sam's Club, your local independent pharmacy, or a Kroger/Safeway/Publix pharmacy. Bring your insurance card. Allow 30 minutes — most of it is paperwork; the shot itself takes about 30 seconds.
Co-administering with flu or COVID shots is permitted but tends to amplify next-day reactogenicity. If you're cautious, space them by a week.
What changes
Most of the payoff is invisible — the thing that doesn't happen. You don't get a phone call from your sister at 6 AM about her face on one side feeling like it's on fire. You don't have to explain to your kids that you'll be in the hospital for a week with what they thought was just a cough. You don't have the conversation with your wife about whether the burning across your ribs is going to ever fully go away.
The invisibility is the catch with vaccines: probabilistically, most people in any given year would not have gotten shingles or been hospitalized for RSV anyway. The payoff lands as a lifetime-cumulative shift in odds. By 75, a third of unvaccinated people will have had a shingles episode. By 85, half will. Of those, 10–20% will have lived with months of nerve pain afterward. Cut that risk by 90% and the realistic future is one where you and the people you know who got the shot watch the people who didn't go through it — and notice the difference.
The RSV vaccine has a sharper short-term payoff because the disease is seasonal. People in long-term care facilities, where outbreaks can flatten an entire floor in a week, see the most direct effect: the year you get the shot is the year you don't end up in the ambulance during your facility's outbreak. For community-dwelling older adults, the payoff is the winter you have a normal head cold instead of pneumonia, and you only find out which winter that was because you didn't get sick.
If the dementia signal holds up — and the evidence is getting stronger, not weaker — the payoff stretches into your 80s. A 20% relative reduction in dementia diagnoses over seven years is not subtle. It's the difference between recognizing your grandchildren and not. The current evidence isn't a guarantee; it's a substantial side bet that the shingles shot you were getting anyway might also be one of the better dementia-prevention moves available — worth weighing especially if you carry APOE ε4, the main genetic risk factor for Alzheimer's, where genuinely preventive levers are thin on the ground.
Two other vaccines in the same older-adult bundle that aren't covered here but belong on the same checklist: the seasonal flu shot (annually, ideally a high-dose or adjuvanted version at 65+) and the pneumococcal series (one or two doses depending on which vaccine, age, and conditions). The COVID vaccine and its updated formulations are a fourth piece of the bundle. If you're getting the shingles or RSV vaccine at the pharmacy, ask which of these you're due for; the system already has your record.
- — The shingles shot does double duty: Shingrix recipients show roughly a fifth lower dementia risk, a rare preventive lever if you carry this gene.
- — Not sure if you're old enough or sick enough to need the RSV shot yet? This walks the eligibility line.
- — These two are the highest-payoff shots on the adult schedule — see the full lineup for everything else you're due.
- — The shingles shot appears to cut dementia risk about a fifth — the same disease these drugs treat once it has already taken hold.
- — Another adult vaccine most people assume the age window closed on — it didn't, and it blocks six cancers.
Substance and claimed effects
This entry covers two recombinant vaccines targeted at older adults: the adjuvanted recombinant zoster vaccine (RZV, marketed as Shingrix, licensed in the US since 2017) and the three currently licensed RSV vaccines for adults — GSK's Arexvy (RSVPreF3-AS01E, prefusion-F + AS01 adjuvant), Pfizer's Abrysvo (bivalent RSVpreF), and Moderna's mResvia (mRNA-1345). The bundling is editorial but practical: both are one-time decisions an immunocompetent older adult makes once, both target high-burden pathogens that disproportionately strike the same age band, both are now ACIP-recommended, both are typically zero out-of-pocket cost for Medicare Part D enrollees post-IRA, and the decision logic (effect size, reactogenicity, the small GBS signal for RSV vaccines) is parallel. Claimed effects: incidence reductions in herpes zoster and postherpetic neuralgia (RZV); incidence reductions in RSV-associated symptomatic lower respiratory tract disease, ED visits, and hospitalizations (RSV vaccines); reduced cardiovascular events following zoster reactivation (RZV, observational); and a probable but still-being-litigated reduction in incident dementia (RZV, multiple natural-experiment and EHR-cohort signals).
Evidence by addressing question
Mechanism
RZV is a subunit vaccine combining recombinant varicella-zoster virus glycoprotein E with the AS01B adjuvant system (MPL + QS-21 liposomal). The mechanism is restoration of VZV-specific CD4+ T-cell immunity, which declines with age and permits reactivation of latent virus from dorsal root ganglia Lal et al. 2015. The adjuvant is what makes the vaccine work in the very-old immune system that responded poorly to the older live-attenuated Zostavax; AS01 drives a Th1-polarized response with substantial reactogenicity as a byproduct.
Arexvy and Abrysvo (and mResvia, the mRNA entrant) deliver the RSV F glycoprotein stabilized in its prefusion conformation. The prefusion-stabilization design is the breakthrough — prior decades of RSV vaccine development failed (and an early formalin-inactivated candidate in the 1960s caused enhanced disease in infants), and stabilizing F in its pre-fusion state exposes neutralization-sensitive epitopes that the post-fusion form hides Papi et al. 2023, Walsh et al. 2023. Arexvy adds AS01E adjuvant; Abrysvo is bivalent (subtypes A and B) and unadjuvanted; mResvia is mRNA-encoded prefusion-stabilized F.
Evidence — RZV efficacy
The pivotal phase-3 trials are ZOE-50 (N≈15,400 adults ≥50, median follow-up 3.2 years) and ZOE-70 (N≈13,900 adults ≥70, pooled follow-up ~3.7 years). Vaccine efficacy against confirmed herpes zoster was 97.2% in ZOE-50 Lal et al. 2015 and 91.3% in ZOE-70 Cunningham et al. 2016. Efficacy against postherpetic neuralgia was 91.2% in adults ≥50 and 88.8% in adults ≥70. Efficacy did not decline meaningfully with age within the trial population — the ≥80 stratum tracked the overall numbers, which is unusual for a vaccine and is attributed to the adjuvant.
Long-term follow-up of ZOE-50/70 participants out to ten years post-second-dose shows residual efficacy against herpes zoster of ~73% at year 10, with anti-gE antibody titers still ~6x baseline Strezova et al. 2022. Real-world post-licensure data from the FDA's Sentinel system and Medicare claims found two-dose effectiveness of 70.1% against herpes zoster and 76.0% against PHN, with single-dose effectiveness substantially lower (~56.9%) — completing the series matters Izurieta et al. 2021. Effectiveness held in adults ≥80 and in those with autoimmune conditions or immunosuppression. Real-world numbers are predictably below RCT numbers (different endpoint adjudication, broader population, single-dose contamination).
In immunocompromised populations RZV efficacy is lower but still substantial. In autologous hematopoietic stem cell transplant recipients, RZV showed efficacy of 68.2% against zoster Bastidas et al. 2019. Comparable signals exist for hematologic malignancy, solid tumor, renal transplant, and HIV cohorts, which is why ACIP extended RZV recommendation to immunocompromised adults ≥19 in 2022 ACIP 2022.
Evidence — RSV vaccine efficacy
AReSVi-006 (Arexvy, N≈24,966 adults ≥60) reported single-season efficacy of 82.6% against RSV-associated lower respiratory tract disease (≥2 lower-respiratory symptoms) and 94.1% against severe RSV-LRTD Papi et al. 2023. Cumulative efficacy across three RSV seasons fell to ~63% against LRTD (manufacturer-reported data, post-publication). The RENOIR trial of Abrysvo (N≈34,284 adults ≥60) reported 66.7% efficacy against ≥2-symptom RSV-LRTD and 85.7% against ≥3-symptom RSV-LRTD in the first season Walsh et al. 2023.
Real-world effectiveness data from CDC's VISION and IVY networks confirms protection against hospitalization. Across the 2023–2024 and 2024–2025 RSV seasons, vaccine effectiveness against RSV-associated hospitalization in adults ≥60 was ~75% in the first year and ~50–60% in the second, with sharper waning in the immunocompromised and adults ≥80 Payne et al. 2025. Whether booster dosing closes the waning gap is an open question; current ACIP guidance is single-dose, not annual.
Evidence — disease burden the vaccines avert
Herpes zoster lifetime risk is approximately 30%, rising to ~50% by age 85 Kawai et al. 2014. US incidence is ~1.2 million cases/year. PHN — pain lasting >90 days after the rash resolves — occurs in roughly 10–18% of zoster cases overall, rising with age (~30% in patients ≥80). PHN is the dominant disability driver: pain can persist for years, is poorly responsive to standard analgesics, and substantially reduces health-related quality of life. Less common but serious zoster complications include herpes zoster ophthalmicus (~10–25% of zoster cases, can cause permanent vision loss), Ramsay Hunt syndrome (facial palsy + auricular zoster), zoster-associated stroke (relative risk roughly 1.3–1.6 in the 30–90 days after zoster), and rare encephalitis or myelitis.
RSV in older US adults causes approximately 60,000–160,000 hospitalizations and 6,000–10,000 deaths annually Hansen et al. 2022. RSV-NET surveillance in 12 states (July 2022–June 2023) found that among 1,634 hospitalized adults ≥60, 17.0% required ICU admission, 4.8% required mechanical ventilation, and 4.7% died Anderson et al. 2023. Severity is comparable to influenza on a per-hospitalization basis; the IVY Network found similar or higher disease severity for RSV than for flu among hospitalized older adults. RSV is also a substantial trigger of COPD and CHF exacerbations.
Evidence — off-target effects (dementia and cardiovascular)
The Welsh natural experiment exploited a sharp date-of-birth eligibility cutoff for the older live zoster vaccine (Zostavax): those born on or after 2 September 1933 were eligible; those born before were not. Comparing the two groups (a clean regression-discontinuity design that controls for confounding by health-seeking behavior — the usual problem in vaccine-outcome observational work), zoster vaccination reduced 7-year incident dementia by 3.5 percentage points absolute, or ~20% relative Eyting et al. 2025. Replicated in a parallel English/Welsh population and in death-certificate data; effect was larger in women.
An EHR cohort using TriNetX data compared adults who switched from Zostavax to Shingrix at the 2017 transition: Shingrix recipients had 17% more dementia-free time over six years versus Zostavax recipients Taquet et al. 2024. If the Wales-style natural experiment captures a ~20% relative reduction from the older live vaccine, Shingrix's signal stacks on top — implying Shingrix's absolute effect on dementia could be larger still, though the comparison is across study designs and the absolute Shingrix-vs-no-vaccine estimate is not yet RCT-tested. Putative mechanisms: prevention of zoster-driven neuroinflammation, prevention of VZV-induced amyloid/tau pathology, and/or generalized AS01 adjuvant immunomodulation that also protects against other neurotropic viruses. The same AS01-adjuvanted RSV vaccine (Arexvy) shows a smaller but parallel dementia signal in early observational data, supporting an adjuvant-mediated mechanism alongside virus-specific effects.
Smaller observational signals: RZV is associated with reductions in major adverse cardiovascular events in the months following what would have been a zoster episode, plausibly through preventing the prothrombotic state that follows acute zoster. Effect sizes are modest and confounded by health-seeker bias even in matched cohorts; this is suggestive evidence, not settled.
Protocol
RZV: two intramuscular doses, second 2–6 months after the first for immunocompetent adults; 1–2 months for immunocompromised. Missing the 6-month window is not a series-restart event — give the second dose as soon as possible CDC 2024. Reactogenicity is moderate-to-substantial: ~78% of recipients report any injection-site pain; ~10% grade-3 (interferes with normal activity) local symptoms; systemic symptoms (myalgia, fatigue, fever, headache, chills) are common and typically peak 1–2 days post-dose, resolving by day 3. The second dose tends to be more reactogenic than the first. No long-term safety signal beyond expected vaccine-class events.
RSV vaccines: single intramuscular dose, ideally late summer/early fall to coincide with the start of RSV season. No revaccination interval currently recommended by ACIP CDC 2025. Reactogenicity is mild-to-moderate; injection site pain in ~50–60%, fatigue in ~30–35%, headache in ~25%, all typically resolving in 1–2 days. The AS01-adjuvanted Arexvy is somewhat more reactogenic than unadjuvanted Abrysvo. No documented difference in clinical effectiveness between the three approved RSV vaccines on currently available real-world data; the choice is generally what's in stock.
Contraindications
RZV: severe allergic reaction to a prior dose or any vaccine component (the AS01 adjuvant is the most common trigger). Active herpes zoster is a deferral indication, not a permanent contraindication — wait until the rash resolves. Pregnancy is a deferral, not relevant to the older-adult target population. RZV does not contain live virus and is safe in immunocompromised patients (the use case ACIP extended in 2022) ACIP 2022.
RSV vaccines: severe allergic reaction to vaccine components. The FDA mandated a Guillain-Barré syndrome warning in 2025 after a postmarketing observational study using Medicare claims estimated approximately 9 excess GBS cases per million Abrysvo doses and 7 per million Arexvy doses within 42 days of vaccination FDA 2025. The signal is real but small in absolute terms (~1 case per 110,000–140,000 doses) and well below the disease burden the vaccines avert. mResvia (mRNA) had no GBS signal in trials or early postmarketing data and is one alternative.
Misconceptions
The most pervasive misconception is that having had shingles confers immunity, so no vaccine is needed. False — recurrence rates are 5–10% within 8 years, and ACIP recommends RZV regardless of prior zoster history (wait until the acute episode resolves). The second-most pervasive: that prior Zostavax means RZV isn't needed. Also false — RZV is recommended for everyone in the target age band, including those who received Zostavax. A third: that RSV is "just a cold." For hospitalized older adults, RSV mortality rivals influenza (~5% in-hospital) and post-discharge functional decline is substantial. A fourth: that the RSV GBS signal is large enough to outweigh benefit. Quantitatively, the benefit-risk balance favors vaccination by ~2–3 orders of magnitude across the recommended age band.
Audience and high-risk subgroups
Current ACIP recommendations (as of mid-2025) CDC 2025, CDC 2024:
- RZV: routine for all immunocompetent adults ≥50; for immunocompromised adults ≥19.
- RSV vaccines: routine single dose for all adults ≥75; single dose for adults 50–74 with risk-elevating conditions (chronic lung disease, cardiovascular disease, diabetes, chronic kidney/liver disease, immunocompromise, severe obesity, hematologic disease, neurologic/neuromuscular conditions affecting respiration, frailty, long-term-care residency) Fleming-Dutra et al. 2025.
The 2025 ACIP update lowered the RSV high-risk age band from 60 down to 50, which catches the earlier-onset COPD and diabetes population. Long-term-care residents are a special case — outbreaks in nursing homes have high attack rates and very high case-fatality, and uptake is much lower than in community-dwelling elders.
Practicalities
US cost (as of 2025): RZV list price ~$200/dose ($400/series); RSV vaccines ~$280–$320/dose. The Inflation Reduction Act eliminated cost-sharing for ACIP-recommended adult vaccines under Medicare Part D starting 1 January 2023; covered Medicare beneficiaries pay $0 out of pocket. Commercial insurance under the ACA preventive-services rule similarly covers ACIP vaccines without cost-sharing. The practical cost is therefore zero for the modal target reader; uninsured cost is $400–$700 total for the pair. Most administration happens at chain pharmacies (Medicare Part D billing is set up at pharmacies, not most physician offices).
Reactogenicity-related lost work time is real for RZV: the 1–3 days of fatigue/myalgia after each dose are typically described as "feeling fluish but functional." Schedule doses on a Friday if the day after is a work day matters. RSV vaccines are notably milder and rarely cause lost activity.
Failure modes
The most common failure mode for RZV is not completing the second dose. CDC and real-world data put two-year second-dose completion rates around 75–80% in commercially insured populations and lower in Medicare; single-dose protection is meaningfully worse (~57% vs 70–97%) and wanes faster. Setting a calendar reminder at the time of the first dose is the highest-leverage protocol nudge. The second failure mode is delaying vaccination "until I'm older" — incidence and severity of both zoster and RSV climb steeply with age, but so does immune response failure to the vaccine; vaccinating at the floor of the eligibility window captures more lifetime benefit than waiting. The third failure mode (RSV-specific) is single-dose protection waning past two seasons in the very elderly — current guidance does not recommend revaccination, but if booster doses are added in future, current vaccinees will need to know.
Stakes
Across the recommended age bands, the consequence of skipping is probabilistic: most readers will go many years without a zoster or RSV event, then encounter one. The clearest individual-level forecasts are tied to age. By 75, lifetime zoster risk has reached ~30% and is climbing; PHN risk conditional on zoster is ~15–20% and climbing with age. RSV hospitalization risk in any given season for an 80-year-old with comorbidities is roughly 1–2%; integrated across remaining lifespan, the cumulative risk of an RSV hospitalization is on the order of 10–20%.
Payoff
Quantitatively, RZV is one of the most efficacious vaccines licensed in adults — efficacy in the high 90s in 50–69 year-olds, falling only to the high 80s in the very elderly. RSV vaccine efficacy against severe disease and hospitalization sits in the 75–90% range in the first season. The combined effect for an immunocompetent 70-year-old who takes both: shingles incidence cut by ~90%, RSV hospitalization cut by ~75%, with downstream effects on PHN, cardiovascular complications of zoster, and probably (under the dementia hypothesis) incident dementia.
Stakeholder + incentive map
RZV: GSK is the sole manufacturer (Merck's Zostavax was discontinued in the US in 2020). The vaccine is profitable but ACIP-recommended on its merits, with US Department of Health and Human Services and CDC endorsement post-2017 review. Independent academic and Cochrane reviews support the efficacy claims.
RSV vaccines: GSK (Arexvy), Pfizer (Abrysvo), Moderna (mResvia). Competitive market, similar pricing, similar guideline coverage. There is some genuine professional debate over whether the 2024 reformulation of ACIP guidance — which moved from "shared clinical decision-making" to routine recommendation at 75+ — went far enough or pulled back too quickly from the original 60+ shared-decision frame. The GBS signal contributed to the more conservative current posture.
Counter-incentives are small: anti-vaccine messaging, occasional medical pundits arguing GBS risk is downplayed. The serious dissent is at the margins (e.g., whether the dementia signal is causal or confounded), not on whether the core indication is justified.
Credibility range
Optimist case
The trials are exceptionally strong by vaccine-trial standards: large N, multi-country, double-blind, placebo-controlled, with PCR-confirmed primary endpoints. Effect sizes are very large — RZV efficacy of 90–97% against shingles is among the highest reported for any vaccine, and RSV vaccine efficacy of 80%+ against LRTD is comparable. Real-world effectiveness, while lower (as is normal), confirms substantial benefit. The dementia signal, while observational, has unusually strong identification (the Wales date-of-birth cutoff is essentially randomized) and has now replicated across continents and vaccine generations Eyting et al. 2025, Taquet et al. 2024. The GBS signal in RSV vaccines is real but tiny relative to disease burden averted. Cost is functionally zero for the target reader. This is one of the highest expected-value preventive interventions available to older adults.
Skeptic case
RZV's reactogenicity is more substantial than older adults are usually warned about, and second-dose completion is meaningfully lower than first-dose uptake. The very-long-term durability of RZV beyond 10 years is unknown — the people the vaccine was given to in their 50s may need a booster by their 80s, and current ACIP guidance is silent on revaccination. The dementia hypothesis remains observational; the absolute magnitude of effect (versus delay vs. true reduction) is unclear. For RSV vaccines, second-season effectiveness waning is real, especially in the immunocompromised and very elderly — the population that most needs protection sees the steepest waning. The Guillain-Barré signal, though small, is biologically plausible (other vaccines have transient GBS signals) and not zero. The transition from ACIP shared-clinical-decision-making at 60+ to a routine recommendation only at 75+ partly reflected weakening confidence in the 60–74 benefit-risk balance for low-risk adults.
Author's call
Both vaccines clear the bar for routine recommendation in their guideline-defined populations by a wide margin. The benefit-risk math is overwhelming for RZV; the math is strong but not overwhelming for RSV vaccines in low-risk 60–74-year-olds (where ACIP rightly defers to risk-stratification). The dementia evidence shouldn't carry the recommendation by itself but reinforces it. Net call: among the highest-evidence and highest-payoff do entries in the older-adult catalogue, with effort and cost approaching zero post-IRA. Evidence score 5, controversy 1.
Population variability
- Age. RZV efficacy holds across the 50–80+ range. RSV vaccine efficacy against severe disease holds across 60–80+, but waning is sharper in adults ≥80 — second-season effectiveness in the very elderly is in the 40–55% range vs. 60–75% in 60–74-year-olds.
- Immunocompromise. RZV is recommended ≥19 in immunocompromised adults with substantially lower but still meaningful efficacy (~50–70% depending on the specific condition). RSV vaccine effectiveness drops in immunocompromised (effectiveness against hospitalization roughly halved versus immunocompetent).
- Sex. Both vaccines work comparably across men and women in trial data. The Wales dementia signal was numerically larger in women, mechanism unclear.
- Frailty / long-term-care residency. Long-term-care residents are a high-leverage subgroup (outbreak risk, very high CFR) and are explicitly named in ACIP's risk-condition list Fleming-Dutra et al. 2025.
- Race/ethnicity. Trial populations were majority white; subgroup analyses do not suggest differential efficacy, but uptake in the US is markedly lower in Black and Hispanic older adults than in non-Hispanic white older adults — an access/equity issue rather than a biological one.
Knowledge gaps
- RZV durability past year 10. Current data extend to ~10 years; whether protection holds at year 15–20 is unknown. A booster strategy for early-vaccinated 50-year-olds has not been studied.
- RSV vaccine revaccination interval. Single-dose protection wanes by season 2–3; whether to revaccinate, and on what interval, is unresolved. ACIP currently recommends against revaccination.
- Dementia hypothesis — magnitude. The relative-effect estimates (20% from Wales; 17% additional dementia-free time from Taquet's EHR analysis) span a range, and absolute effects depend on baseline dementia incidence. RCT-grade confirmation is unlikely on ethical grounds (can't withhold an approved vaccine to study a secondary endpoint).
- Mechanism of dementia effect. Virus-specific (preventing zoster reactivation neuroinflammation) vs. adjuvant-mediated (AS01's general immunomodulation) is not resolved. The smaller Arexvy dementia signal favors adjuvant contribution.
- GBS causality. The RSV vaccine GBS signal is statistical, not biologically anchored. Whether mResvia is signal-free or simply less studied is open.
- Combination administration. Co-administration with influenza or COVID vaccines is permitted but increases reactogenicity; whether immunogenicity is preserved with co-administration is being studied.
Scope per brief. The brief bundled two vaccines under one entry. Kept them together — they share target population, decision frame (one-time choice after 50/75), payment frame (free on Medicare Part D post-IRA), and the dossier supports them as a paired older-adult prevention bundle. Splitting them into two entries would force the reader to weigh them twice with the same logic.
Category choice. Picked screening over medical. The renderer's Screening & Prevention bucket is the natural home for vaccinations; medical reads more like therapeutic interventions and conditions.
Audience scoping. Set ages to 40-59 and 60+. The brief targets older adults; the modal reader who would act on this starts in their 50s. The body notes the immunocompromised 19+ Shingrix indication and the 50-74 high-risk RSV indication, but most 18-39 readers won't act, so excluding that band from the audience tag is honest scoping rather than under-coverage.
Contraindications field left empty. The closed-vocabulary tokens (pregnancy, autoimmune, blood-thinners, etc.) don't map to the real contraindications for these vaccines in the target population — severe allergic reaction to vaccine components, active shingles (a deferral, not a stop), and the GBS warning on RSV vaccines. All three are surfaced in the contraindications addressing section.
Longevity score (4 vs 3). Borderline call. RSV vaccines avert ~6,000–10,000 US deaths/year in older adults; Shingrix doesn't directly prevent deaths but a 20% relative dementia reduction (if it holds) would be one of the larger effects in the catalogue. Combined with cardiovascular benefit signals, settled on 4. If the dementia signal weakens in further studies, this drops to 3.
Dementia evidence — how heavily to lean. Considered understating the dementia signal because it's still observational. The Wales natural experiment Eyting et al. 2025 has unusually clean identification (regression-discontinuity on date-of-birth eligibility) and replicates across populations and vaccine generations, so I gave it real estate in evidence, stakes, and payoff, but explicitly hedged the absolute claim in payoff ("if the signal holds up"). RCT confirmation is unlikely on ethical grounds, so observational evidence is what the field will have.
RSV dosing cadence. Treated as once per current ACIP guidance even though revaccination may be added in future. Flagged in failure-modes that boosters are an open question.
Cost score 1 not 0. Functionally $0 for the modal Medicare/commercial-insurance reader, but list prices are real and the uninsured do pay ~$400 for the Shingrix series. Picked 1 rather than 0 to be honest about the underlying price.
Future-link candidates. Flu vaccine (high-dose/adjuvanted for 65+), pneumococcal vaccines (PCV20/PCV21, PPSV23), COVID vaccine (annual). All four belong on the same older-adult checklist; the closing addressing section points at them.
Separate-entry candidates. The dementia hypothesis itself — if the evidence base continues to strengthen — could warrant its own entry that synthesizes Wales + Taquet + future studies and is cross-referenced from this one and from any future infection-and-cognitive-decline entry.
Reader-prose hedging on adjuvant terminology. Used "AS01 adjuvant" in body once but with felt-experience anchor ("the hard punch is also why you feel rough"). Considered cutting the term entirely; left it because the reactogenicity story doesn't make sense without it, and readers searching for the term should find it.
Shingles and RSV Vaccines
Functionally $0 for the target reader. Medicare Part D enrollees pay nothing out of pocket since the Inflation Reduction Act took effect 1 January 2023; ACA preventive-services coverage applies similarly to commercial insurance. Uninsured list prices are ~$200/RZV dose and ~$280–$320/RSV dose.
One appointment for the RSV vaccine; two appointments 2–6 months apart for RZV. Each visit is a 5–10 minute shot. The real cost is 1–3 days of post-RZV reactogenicity (myalgia, fatigue, sometimes fever) — substantial enough that scheduling around a work day matters, but a once-in-life cost.
Two pivotal phase-3 RCTs for RZV (ZOE-50, ZOE-70, N≈29,000 combined; Lal 2015; Cunningham 2016) with 10-year extension data (Strezova 2022); two pivotal RCTs for the two leading RSV vaccines (AReSVi-006 N≈25,000, RENOIR N≈34,000; Papi 2023; Walsh 2023). Real-world effectiveness studies in Medicare, Sentinel, and VISION/IVY networks confirm trial results. ACIP and FDA-endorsed; among the strongest evidence bases in adult preventive medicine.
RZV efficacy against herpes zoster of 91–97% in ZOE-50/70 (Lal 2015; Cunningham 2016) with durable PHN prevention; RSV vaccines 75–94% effective against severe LRTD in AReSVi-006 and RENOIR (Papi 2023; Walsh 2023). RSV-related mortality in US older adults is ~6,000–10,000/year (Hansen 2022); RSV-NET hospitalization case fatality is ~5% (Anderson 2023). Causal-grade natural experiment from Wales (Eyting 2025) and the Taquet 2024 EHR cohort indicate ~20% relative reduction in incident dementia after zoster vaccination, with smaller cardiovascular benefit signals. Together this is one of the highest-impact preventive bundles available to adults ≥50.